Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
P/B ratio for Adicet Bio, Inc. (ACET)
P/B ratio as of 2023: 0.48
According to Adicet Bio, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.48. At the end of 2022 the company had a P/B ratio of -1.54.
P/B ratio history for Adicet Bio, Inc. from 2008 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 0.48 |
| 2022 | -1.54 |
| 2021 | -3.22 |
| 2020 | -0.97 |
| 2019 | -2.59 |
| 2018 | 17.25 |
| 2017 | 6.12 |
| 2016 | 1.05 |
| 2015 | 1.09 |
| 2014 | 1.15 |
| 2013 | 1.38 |
| 2012 | 1.57 |
| 2011 | 1.60 |
| 2010 | 1.78 |
| 2009 | 1.72 |
| 2008 | 1.72 |